GHK-Cu + MOTS-c Stack: Evidence, Mechanism Overlap, and Protocol

GHK-Cu on its own

GHK-Cu is the copper(II) complex of GHK, a tripeptide found in human plasma, saliva and urine that declines with age; its proposed repair actions come from laboratory and animal work, not proven human effects [8].

In an evaluator-blinded trial of 86 patients with venous stasis ulcers, a 0.4% tripeptide copper complex cream was no different from vehicle for ulcer size [2]. In a trial of 13 patients after CO2 laser resurfacing, objective measures found no significant difference in redness, wrinkles or skin quality, while a patient questionnaire favoured GHK-Cu (P=.04) [3]. A 2026 systematic review of 64 records called the human literature thin and fragmented [9].

MOTS-c on its own

MOTS-c is a 16-amino-acid peptide encoded in mitochondrial DNA, first reported in 2015 [1][10]. In mice it prevented diet-induced obesity and insulin resistance [10], and in another mouse study a late-life schedule of 15 mg/kg three times weekly from 23.5 months of age lengthened median lifespan from 912 to 970 days [1][4].

In people, studies measured the body's own MOTS-c. In 30 healthy adults randomized to endurance exercise, resistance exercise or control, circulating MOTS-c showed only a trend to increase after endurance exercise and was not related to fitness [11]. FDA found no published study in which MOTS-c was given to a person [1].

Do the mechanisms overlap?

No shared pathway has been shown. GHK is reported, from laboratory and animal work, to stimulate collagen and proteoglycan production, modulate metalloproteinases, and attract immune and endothelial cells to injuries [8]. MOTS-c, in mice, appears to act mainly on skeletal muscle, inhibiting the folate cycle and activating AMPK [10]; FDA says its molecular targets are unknown and notes an in-vitro study in which MOTS-c is quickly broken down in human blood, which raises the question of whether injecting it produces active levels in people [1]. Whether combining the two changes either effect is unknown.

Is there a protocol?

No studied one. There is no FDA-approved dose of either peptide and no human dosing study of MOTS-c: the products nominated to FDA were 5 mg and 10 mg subcutaneous injections, and rodent doses (0.5 to 15 mg/kg) cannot be converted into human doses [1].

Regulatory and antidoping status

Neither is an approved medicine, and no FDA-approved drug contains GHK-Cu [5]. Non-injectable GHK-Cu is in category 1 of FDA's interim policy (under evaluation for the bulks list); injectable GHK-Cu is in the 'nominated but withdrawn' table, where FDA cites immunogenicity risk from aggregation and peptide impurities and limited human data [5][12]. MOTS-c is in none of the three categories on FDA's list for state-licensed pharmacies and physicians, and FDA staff recommended in July 2026 against adding it to the bulks list, citing missing human safety and effectiveness data, no animal toxicity studies and gaps in characterization [5][1]. The Pharmacy Compounding Advisory Committee voted the other way on July 23, 2026, which is non-binding advice [13]. HHS's October 2026 draft enforcement-discretion policy names MOTS-c acetate (subcutaneous or intramuscular injection) among six peptides and does not name GHK-Cu; it is a non-binding draft, not an approval [15][16]. WADA names MOTS-c in S4.4.1, prohibited at all times; GHK-Cu is not named, but WADA's 2027 notes say peptides not specifically named may still be prohibited [6][14][7].